Condition: AVP Deficiency · Diabetes Insipidus · Sponsor: University Hospital, Basel, Switzerland
The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.
This description comes directly from the study's public registry record.
Andi Nikaj, MD · +41 61 328 57 43 · andi.nikaj@usb.ch
Ursula Gobrecht-Keller, MD · +41 61 32 86028 · ursula.gobrecht@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07361263